Journal Mobile Options
Table of Contents
Vol. 15, No. 2, 2002
Issue release date: March–April 2002
Skin Pharmacol Appl Skin Physiol 2002;15:85–91
(DOI:10.1159/000049394)

Different Skin Thinning Potential of Equipotent Medium-Strength Glucocorticoids

Korting H.C. · Unholzer A. · Schäfer-Korting M. · Tausch I. · Gassmueller J. · Nietsch K.-H.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

In this study, we investigated the effect of prednicarbate, mometasone furoate and betamethasone 17-valerate on total skin thickness over a treatment period of 6 weeks. The study was conducted as a double-blind, placebo-controlled randomized clinical trial with a confirmatory approach. The influence of these drugs on healthy human skin under non-occlusive conditions was assessed by measuring total skin thickness and epidermal thickness using 20 and 50 MHz sonography, respectively. Epidermal surface structure was evaluated using profilometry. Visual assessment addressed signs of atrophy and formation of telangiectasia. The reduction of total skin thickness induced by prednicarbate was clearly less than that caused by betamethasone 17-valerate and mometasone furoate. Prednicarbate led to a higher degree of skin thinning than vehicle. For technical reasons, epidermal thickness could not be reliably evaluated with 50 MHz sonography. Profilometry did not demonstrate any differences between treatments. Visible signs of atrophy or telangiectasia were detected in two subjects each upon betamethasone 17-valerate and mometasone furoate, but not upon prednicarbate or its vehicle. Prednicarbate is a topical glucocorticoid with an improved benefit/risk ratio, as it causes less skin atrophy than the equipotent betamethasone 17-valerate.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Sulzberger MB, Witten VH: Effect of topically applied compound F in selected dermatoses. J Invest Dermatol 1952;19:101–102.
  2. Schäfer-Korting M, Schmid M-H, Korting HC: Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept. Drug Safety 1996;14:375–385.

    External Resources

  3. Schackert C, Korting HC, Schäfer-Korting M: Qualitative and quantitative assessment of the benefit-risk ratio of medium potency topical corticosteroids in vitro and in vivo. Characterisation of drugs with an increased benefit-risk ratio. Biodrugs 2000;13:267–277.
  4. Epstein NN, Epstein WL, Epstein JH: Atrophic striae in patients with inguinal intertrigo. Arch Dermatol 1963;87:450–457.
  5. Korting HC, Kerscher MJ, Schäfer-Korting M: Topical glucocorticoids with improved benefit/risk ratio: Do they exist? J Am Acad Dermatol 1992;27:87–92.
  6. Korting HC, Vieluf D, Kerscher M: 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. Eur J Clin Pharmacol 1992;42:159–161.
  7. Schäfer-Korting M, Korting HC, Kerscher MJ, Lenhard S: Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids. Clin Pharmacol Ther 1993;54:448–456.
  8. Katz HI, Prawer SE, Mooney JJ, Samson CR: Preatrophy: Covert sign of thinned skin. J Am Acad Dermatol 1989;20:731–735.

    External Resources

  9. Tan CY, Marks R, Payne P: Comparison of xeroradiographic and ultrasound detection of corticosteroid induced dermal thinning. J Invest Dermatol 1981;76:126–128.

    External Resources

  10. Tan CY, Statham B, Marks R, Payne P: Skin thickness measurement by pulsed ultrasound: Its reproducibility, validation and variability. Br J Dermatol 1982;106:657–667.
  11. El Gammal S, Hoffmann K, Auer T, Korten M, Altmeyer P, Höss A, Ermert H: A 50-MHz high-resolution ultrasound imaging system for dermatology; in Altmeyer P, El Gammal S, Hoffmann K (eds): Ultrasound in Dermatology. Berlin, Springer, 1992, pp 297–322.
  12. El Gammal S, Altmeyer P, Auer T, Kaspar K, Hoffmann K, Passmann C, Ermert H: Der Stellenwert der 20, 50 und 100 MHz Sonographie in der Dermatologie. Akt Dermatol 1995;21:11–21.
  13. El Gammal S, Hoffmann K, Stücker M, Altmeyer P: Bildgebende Verfahren in der Dermatologie. Hautarzt 1997;48:432–450.
  14. Gassmüller J, Kecskés A, Jahn P: Stylus method for skin surface contour measurement; in Serup J, Jemec BE (eds): Non-Invasive Methods and the Skin. Boca Raton, CRC Press, 1995, pp 83–88.
  15. Kerscher MJ, Korting HC, Mehringer L, Mätzig R: 0.05% clobetasol 17-propionate cream and ointment but not the corresponding 0.1% triamcinolone acetonide preparations increase skin surface roughness: A possible dissociation of unwanted epidermal and dermal effects. Skin Pharmacol 1996;9:120–123.
  16. Dykes PJ, Hill S, Marks R: Assessment of the atrophogenicity potential of corticosteroids by ultrasound and by biopsy under occlusive and nonocclusive conditions; in Christophers E, Schöpf E, Kligman AM, Stoughton RB (eds): Topical Corticosteroid Therapy: A Novel Approach to Safer Drugs. New York, Raven Press, 1988, pp 111–118.
  17. Kerscher MJ, Korting HC: Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound. Acta Derm Venereol (Stockh) 1992;72:214–216.
  18. Kerscher MJ, Hart H, Korting HC, Stalleicken D: In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther 1995;33:187–189.

    External Resources

  19. Schalla W, Schorning S: Potency assessment of topical corticoids in the vasoconstrictor assay and on tuberculin induced inflammation. Skin Pharmacol 1991;4:191–204.
  20. Ljunggren B, Möller H: Influence of corticosteroids on ultraviolet light erythema and pigmentation in man. Arch Dermatol Forsch 1973;248:1–12.

    External Resources

  21. Hanifin J, Abrams B, Cherill R: Management of atopic dermatitis with prednicarbate emollient cream 0.1%, a non-halogenated prednisolone derivative. J Geriatr Dermatol 1994;2:119–127.
  22. Lawlor F, Black AK, Greaves M: Prednicarbate 0.25% ointment in the treatment of atopic dermatitis: A vehicle-controlled double-blind study. J Dermatol Treat 1995;6:233–235.
  23. Vogt HJ, Höhler T: Controlled studies of intraindividual and interindividual design for comparing corticosteroids clinically; in Christophers E, Schöpf E, Kligman AM, Stoughton RB (eds): Topical Corticosteroid Therapy: A Novel Approach to Safer Drugs. New York, Raven Press, 1988, pp 169–179.
  24. Alpermann HG: Prednicarbate: Dose-response relations in animal models; in Christophers E, Schöpf E, Kligman AM, Stoughton RB (eds): Topical Corticosteroid Therapy: A Novel Approach to Safer Drugs. New York, Raven Press, 1988, pp 39–48.
  25. Gysler A, Lange K, Korting HC, Schäfer-Korting M: Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. Pharm Res 1997;14:793–797.

    External Resources

  26. Gysler A, Kleuser B, Sippl W, Lange K, Korting HC, Höltje H-D, Schäfer-Korting M: Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin. Pharm Res 1999;16:1386–1391.
  27. Pörtner M, Möllmann H, Rohdewald P: Glucocorticoid receptors in human synovial tissue and relative receptor affinities of glucocorticoid-21-esters. Pharm Res 1988;10:623–627.

    External Resources

  28. Lange K, Kleuser B, Gysler A, Bader M, Maia C, Scheidereit C, Korting HC, Schäfer-Korting M: Cutaneous inflammation and proliferation in vitro: Differential effects and mode of action of topical glucocorticoids. Skin Pharmacol Appl Skin Physiol 2000;13:93–103.
  29. Gormar FE, Bernd A, Holzmann H: The effect of hydrocortisone aceponate on proliferation, total protein synthesis and collagen synthesis in human skin fibroblasts in vitro. Arzneimittelforschung 1990;40:192–196.

    External Resources

  30. Hein R, Korting HC, Mehring T: Differential effect of medium potent nonhalogenated double-ester-type and conventional glucocorticoids on proliferation and chemotaxis of fibroblasts in vitro. Skin Pharmacol 1994;7:300–306.
  31. Bamberger CM, Bamberger AM, DeCastro M, Chrousos GP: Glucocorticoid receptor β, a potential endogenous inhibitor of glucocorticoid actions in humans. J Clin Invest 1995;95:2435–2441.
  32. Bamberger CM, Bamberger AM, Wald M, Chrousos GP, Schulte HM: Inhibition of mineral corticoid activity by the beta-isoform of the human glucocorticoid receptor. J Steroid Biochem Mol Biol 1997;60:42–50.
  33. Levy J, Gassmüller J, Schröder G, Audring H, Sönnichsen N: Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness. Skin Pharmacol 1994;7:231–236.

    External Resources

  34. Lubach D, Platschek H: Steroidbedingte Gesichtshautschädigungen nach Anwendung von Prednicarbat. Hautarzt 1990;41:43–45.
  35. Santos Maia C, Mehnert W, Schäfer-Korting M: Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int J Pharm 2000;196:165–167.
  36. Schäfer-Korting M, Korting HC: Liposome preparations – A step forward in topical drug therapy for skin disease. A review. J Am Acad Dermatol 1989;21:1271–1275.

    External Resources

  37. Korting HC, Zienicke H, Schäfer-Korting M, Braun-Falco O: Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris. Eur J Clin Pharmacol 1990;39:349–351.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50